Canada markets closed

Rakovina Therapeutics Inc. (RKV.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0750+0.0100 (+15.38%)
At close: 01:07PM EST
Full screen
Previous Close0.0650
Open0.0750
Bid0.0700 x N/A
Ask0.0750 x N/A
Day's Range0.0750 - 0.0750
52 Week Range0.0050 - 0.1600
Volume4,000
Avg. Volume16,695
Market Cap5.237M
Beta (5Y Monthly)-0.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update

    VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced financial results for the quarter ended September 30, 2023, and provided a corporate update. Corporate highlights during the past quarter included: On November 27, 2023, we announced the appointment of Prof. Artem Cher

  • GlobeNewswire

    Rakovina Therapeutics Welcomes Prof. Artem Cherkasov to the Company’s Scientific Advisory Board

    VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response inhibitors (DDRi) to address high unmet medical needs in the treatment of cancer, today announced the appointment of Prof. Artem Cherkasov to the Company’s Scientific Advisory Board. Prof. Cherkasov is a Professor in the Department of Urologic Sciences, Faculty of Medicine at the University of B

  • GlobeNewswire

    Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

    VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response (DDR) inhibitors to address high unmet medical needs in the treatment of cancer, today announced the appointment of Prof. Petra Hamerlik, Chair of Translational Neuro-Oncology at the University of Manchester and former CNS Cancer Bioscience Lead at AstraZeneca plc, to its Scientific Advisory Boa